Salmeterol is a long-acting beta2-adrenergic agonist, or LABA, and one of the two active ingredients in combination inhalers for asthma and chronic obstructive pulmonary disease. In both products listed here it is paired with the corticosteroid fluticasone.
Asthma, Chronic Obstructive Pulmonary Disease
25/125 · 25/250mcg
Seroflo Inhaler combines fluticasone and salmeterol in a pressurised inhaler for asthma and COPD. You can choose from several strengths and pack sizes. You see the price per inhaler for each option.
Asthma, Chronic Obstructive Pulmonary Disease
250/50 · 500/50mcg
Fluticasone with salmeterol is an inhaler for asthma and chronic obstructive pulmonary disease. You can choose from multiple strengths and pack sizes. Each option lists its price per inhaler.
Combination inhalers containing salmeterol and fluticasone are used for asthma and for chronic obstructive pulmonary disease. Salmeterol supplies the long-acting bronchodilator effect; fluticasone is the inhaled corticosteroid. Both conditions sit under Respiratory Health, with separate pages on Asthma and Chronic Obstructive Pulmonary Disease.
Salmeterol stimulates beta-2 receptors in the lungs. Activating these receptors relaxes the smooth muscle lining the bronchial tubes, so the airways narrow less easily. The effect is sustained over several hours, which is what separates it from a short-acting reliever.
Two inhalers are listed here. Seroflo Inhaler is supplied in 25/125 mcg and 25/250 mcg strengths, and Fluticasone + Salmeterol in 250/50 mcg and 500/50 mcg. Each contains fluticasone and salmeterol and is used for asthma and COPD. Pharmacy partners in India prepare and ship orders to Malaysia in discreet packaging.
Salmeterol carries a boxed warning that long-acting beta2-adrenergic agonists increase the risk of asthma-related death, and these medicines also raise the risk of asthma-related hospitalisation in paediatric and adolescent patients. The combination should be used only for patients whose asthma is not adequately controlled on a long-term asthma control medication alone, or whose severity warrants both an inhaled corticosteroid and a LABA. Once control is achieved, treatment should be stepped down where possible; it is not meant for patients already controlled on low- or medium-dose inhaled corticosteroids.
Salmeterol can produce a clinically significant cardiovascular effect in some patients, as measured by pulse rate, blood pressure and symptoms. Excessive beta-adrenergic stimulation has been associated with seizures, angina, hypertension or hypotension, tachycardia at rates up to 200 beats per minute, arrhythmias, nervousness, headache, tremor, palpitation, nausea, dizziness, fatigue, malaise and insomnia. Beta-agonist medicines may also cause significant hypokalaemia in some patients, though the fall in serum potassium is usually transient and does not require supplementation.
Last updated
